biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s): BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs

Bullboard Posts

Comment by BearDownAZon Nov 20, 2018 10:44pm

99 Views

Post# 29002921

RE:News: Lymphing along to better days...Links

Exciting news and nice corporate presentation. However, it wasn't clear to me xB3-001 showed enhanced BBB penetration relative to TZM alone in this NHP study. Did I miss something? Is the accumulation of xB3-001 in the cervical lymph nodes a surrogate for BBB penetration?

BearDownAZ

Bullboard Posts

Paramount Resources signs $3.32 billion asset sale